Amendments to the Claims

1. (Currently Amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug ~~derivative~~ thereof;



(I)

wherein ;

R_1 is ~~selected from groups (a), (b), and~~ (c) wherein;

~~(a) is C_7-C_{20} alkyl, C_7-C_{20} haloalkyl, C_7-C_{20} alkenyl, C_7-C_{20} alkynyl, carbocyclic radical, or heterocyclic radical, or~~

~~(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or~~

(c) is the group -(L_1)-R_{11}; where, -(L_1)- is a divalent linking group of 1 to 8 atoms and where R_{11} ~~is a group selected from (a) or (b)~~ is –$(CH_2)_m$-R_{12};

R_2 is hydrogen, or C1-C4 alkyl ~~a group containing 1 to 4 non-hydrogen atoms plus any required hydrogen atoms~~;

R_3 is -(L_3)- Z, where -(L_3)- is a divalent linker group selected from a bond or ~~a divalent group selected from~~:



,

,

,

or

-CH2-

and Z is ~~selected from~~ a group represented by the formulae,



;



~~or~~



wherein, X is oxygen or sulfur; and R_a is selected from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl and -CN;

R_4 is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R_5 is selected from hydrogen, a non-interfering substituent, or the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1 to 8;

R_6 and R_7 are selected from hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl;~~non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s)~~.

2. (Currently Amended) The compound of claim 1 wherein R_2 is hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, -O-(C_1-C_3 alkyl), -S-(C_1-C_3 alkyl), and C_3-C_4 cycloalkyl~~, CF_3, halo, NO_2, CN, or SO_3~~.

3. (Original) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L_h)-, for R_4 is selected from a group represented by the formula;



where Q_2 is selected from the group -(CH_2)-, -O-, -NH-, -C(O)-, and -S-, and each R_{40} is independently selected from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl, and halo.

4. (Currently Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for R_4 is a divalent group selected from,



,



,



,



,



or



where R_{40}, R_{41}, R_{42}, and R_{43} are each independently selected from hydrogen, C_1-C_8 alkyl.

5. (Canceled)

6. (Currently Amended) The compound of claim 1 wherein R_5 is the group, -(L_a)-(acidic group) and wherein the ~~(~~acidic group~~)~~ is ~~selected from the group~~:

~~-5-tetrazolyl,~~

~~-SO_3H,~~



,





,



,



,



or



-COOH.

~~where R_{80} is a metal or C_1-C_8 alkyl and R_{81} is an organic substituent or CF_3.~~

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Original) The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond.

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Original) The compound of claim 1 wherein R_4 is the group, -(L_C)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH, (C_1-C_6)alkoxy, (C_7-C_{14})alkaryloxy, (C_2-C_8)alkenyloxy, (C_7-C_{14}) aralkyloxy, (C_7-C_{14})aralkenyloxy and aryloxy; and

wherein R^{4b} is independently selected from the group consisting of H, $(C_1$-$C_6)$alkyl, arylalkyl, heteroaryl and aryl.

19. (Canceled)

20. (Original) A compound ~~of claim 1~~ selected from the group ~~consisiting~~ of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and

2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. (Canceled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Original) A method of inhibiting $sPLA_2$ mediated release of fatty acid comprising: contacting $sPLA_2$ with a therapeutically effective amount of indole compound as claimed in claim 1.

24. (Currently Amended) A method of treating a mammal, ~~including a human,~~ to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises administering to said mammal a thrapeutically effective amount of an indole compound as claimed in Claim 1.

25. (Currently Amended) A ~~compound of claim 1 or a~~ pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Canceled)

27. (Canceled)